EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unusual Partners: γδ-TCR-Based T Cell Therapy in Combination with Oncolytic Virus Treatment for Diffuse Midline Gliomas

Konstantinos Vazaios iD, Patricia Hernández López, Tineke Aarts-Riemens, Annet Daudeij, Vera Kemp iD, Rob C Hoeben iD, Trudy Straetemans, Esther Hulleman iD, Friso G Calkoen iD, Jasper van der Lugt iD, Jürgen Kuball iD

International Journal of Molecular Sciences · 28.02.2025 · 26 (5) · 2167

DOI: 10.3390/ijms26052167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.02.2025. Verfasst von Konstantinos Vazaios und 10 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Glioma, Oncolytic Virotherapy, Oncolytic Viruses, Receptors, Antigen, T-Cell, gamma-delta. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Inspire2live, Choir4hope, Princess Maxima Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Due to the minimal survival benefits of existing therapies for pediatric diffuse midline glioma (DMG) patients, new therapeutic modalities are being investigated. Immunotherapies such as CAR-T cells and oncolytic viruses (OVs) are part of these efforts, as evidenced by the increasing number of clinical trials. αβ T cells engineered with a high-affinity γ9δ2 T-cell receptor (TEGs) are immune cells designed to target metabolic changes in malignant or virally infected cells via BTN2A1 and BTN3A. Because the expression of BTN2A1 and BTN3A can be altered in tumor and infected cells, combining TEGs and OVs could potentially enhance the anti-tumor response. We investigated this hypothesis in the following study. We demonstrate that TEGs can indeed target DMG, which expresses BTN2A1 and BTN3A at varying levels, and that OVs can further enhance the expression of BTN3A—but not BTN2A1—in DMG. Functionally, TEGs killed DMG cell cultures, and this killing was further increased after OV infection of the DMGs with either adenovirus Δ24-RGD or reovirus R124 under suboptimal conditions. However, this additive effect was lost when γ9δ2 TCR–ligand interaction was boosted by pamidronate. This study demonstrates the additive effect of combining OVs and Vγ9Vδ2 TCR-engineered immune cells under suboptimal conditions and supports a combination strategy to enhance the efficacy of both therapeutic modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaOncolytic VirotherapyOncolytic VirusesReceptors, Antigen, T-Cell, gamma-deltaImmunotherapy, AdoptiveT-LymphocytesBrain NeoplasmsHumansCell Line, TumorCombined Modality Therapy

Stichwörter der Autor:innen

?9?2TCRD24-RGDR124TEGsdiffuse midline gliomaimmune-oncologyimmunotherapyoncolytic viruses

Substanzen

Receptors, Antigen, T-Cell, gamma-delta

Autor:innen und Institutionen

  • Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, The Netherlands.
  • Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden University, 2333 ZC Leiden, The Netherlands.
  • Department of Hematology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.

ORCID-Profile: Konstantinos Vazaios, Vera Kemp, Rob C Hoeben, Esther Hulleman, Friso G Calkoen, Jasper van der Lugt, Jürgen Kuball

Förderung

  • Inspire2live
  • Choir4hope
  • Princess Maxima Foundation
  • KWF 12586, 13043, 13493, 15614, 15570
  • Oncode Accelerator
  • Dutch Research Council
  • Dutch Foundation

Zitieren

APA

Vazaios, K., Hernández López, P., Aarts-Riemens, T., Daudeij, A., Kemp, V., Hoeben, R. C., Straetemans, T., Hulleman, E., Calkoen, F. G., van der Lugt, J., & Kuball, J. (2025). Unusual Partners: γδ-TCR-Based T Cell Therapy in Combination with Oncolytic Virus Treatment for Diffuse Midline Gliomas. International Journal of Molecular Sciences, 26(5), 2167. https://doi.org/10.3390/ijms26052167

Vancouver

Vazaios K, Hernández López P, Aarts-Riemens T, Daudeij A, Kemp V, Hoeben RC, et al. Unusual Partners: γδ-TCR-Based T Cell Therapy in Combination with Oncolytic Virus Treatment for Diffuse Midline Gliomas. International Journal of Molecular Sciences. 2025;26(5):2167. doi:10.3390/ijms26052167

BibTeX
@article{Vazaios2025,
  author = {Vazaios, Konstantinos and Hernández López, Patricia and Aarts-Riemens, Tineke and Daudeij, Annet and Kemp, Vera and Hoeben, Rob C and Straetemans, Trudy and Hulleman, Esther and Calkoen, Friso G and van der Lugt, Jasper and Kuball, Jürgen},
  title = {Unusual Partners: γδ-TCR-Based T Cell Therapy in Combination with Oncolytic Virus Treatment for Diffuse Midline Gliomas},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {5},
  pages = {2167},
  doi = {10.3390/ijms26052167}
}
Kostenlos starten →